United Orthopedic Corporation · TPEX:4129

United Orthopedic — 2020 Investor Conference

22 slides from United Orthopedic's conference presentation, Dec 11, 2020

  1. Slide 1: United Orthopedic Corporation 2020 Investor Conference

    United Orthopedic Corporation 2020 Investor Conference Jason Lin December 11, 2020

  2. Slide 2: Safe Harbor Notice

    Safe Harbor Notice Except for historical information set forth herein, this presentation contains certain forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from what may be expressed or implied by such statements. Investors sh

  3. Slide 3: Agenda

    Agenda  Financial Results (for the first 3 quarters of 2020)  Business Update  Q&A

  4. Slide 4: Revenue & Net Profit

    Revenue & Net Profit (NT$ thousands) (consolidated) 1,800,000 900,000 0 Q1~Q3 2019 Q1~Q3 2020 Revenue 1,790,819 1,663,664 Net Profit 77,937 47,434 EPS 0.98 0.38  Due to the impact of COVID-19 , the company’s revenue decreased 7% year-over- year, accompanied a decline in profit in the first 3 quarte

  5. Slide 5: Operating Results

    Operating Results Revenue Trend Chart Financial Ratios 75% (NT$ millions) 646 646 650 72% 71% 564 15% 581 20% 16% 523 19% 491 17% 15% 69% 17% 83% 85% 81% 80% 85% 83% 84% 63% 60% Q1'19 Q2'19 Q3'19 Q4'19 Q1'20 Q2'20 Q3'20 Q1'19 Q2'19 Q3'19 Q4'19 Q1'20 Q2'20 Q3'20 Sales(UOC) Sales(A-Spine) Margin% OP E

  6. Slide 6: Operating Expense

    Operating Expense (NT$K) Q1~Q3 2019 Q1~Q3 2020 YoY (2019 vs. 2020) Revenue 1,790,819 1,663,664 -7% (127,155) Sales Exp. 903,253 50% 829,296 50% (73,957) ADM Exp. 170,268 10% 162,894 10% (7,374) R&D Exp. 130,897 7% 118,691 7% (12,206) Total Exp. 1,204,418 67% 1,110,881 67% (93,537) 6

  7. Slide 7: Numbers of Surgery

    Numbers of Surgery 436,719 cases implanted worldwide

  8. Slide 8: 8 Branches 40 Countries

    8 prancHes 40 countries (©) Switzerland once O)) Re. 23 we... werner

  9. Slide 9: Revenue Breakdown (2019 vs. 2020)

    Revenue Breakdown (2019 vs. 2020)  Customers build up more stocks for the future needs as signs pandemic ebbing in China.  The contribution of new Oncology product eased the COVID-19 impact in USA. (NT$ thousands) 500,000 -9% 400,000 -13% 300,000 -25% -1% -7% +7% 200,000 100,000 0 9 TW INTL's USA

  10. Slide 10: Revenue by Regions (2019 vs. 2020)

    Revenue by Regions (2019 vs. 2020) Q1~Q3’19 Q1~Q3’20 JPN 1% JPN 2% OEM 0% OEM0% A-Spine TW A-Spine 17% TW 28% 16% 27% EU 14% EU 15% INTL's INTL's China USA 14% China 11% 12% 14% USA 14% 15%

  11. Slide 11: USA Market Development

    USA Market Development  New Oncology product (USTAR II) launched Sales Performance in Q3’20 with high price and increased the (US$ millions) revenue effectively. 3.8 3.1 3.0 18 2.5 16 2.4 2.3 2.4 13 8 6 Jul'20 Aug'20 Sep'20 Oct'20 Nov'20 Q1'19 Q2'19 Q3'19 Q4'19 Q1'20 Q2'20 Q3'20

  12. Slide 12: China Market Development

    China Market Development Sales Performance  Chinese brand name products are planned 58 (RMB millions) to be launched in the second half of 2021. 44 42 40 35 32 30 Q1'19 Q2'19 Q3'19 Q4'19 Q1'20 Q2'20 Q3'20 12

  13. Slide 13: Europe Market Development

    Europe Market Development Sales Performance (EUR millions) 3.1 2.9 2.9 2.7 2.6 2.2 1.3 Q1'19 Q2'19 Q3'19 Q4'19 Q1'20 Q2'20 Q3'20

  14. Slide 14: Japan Market Development

    Japan Market Development Sales Performance  HIP has earned a very positive feedback from Japan market. (JPY millions) 50 50 41 30 27 25 20 Q1'19 Q2'19 Q3'19 Q4'19 Q1'20 Q2'20 Q3'20

  15. Slide 15: Spine Business Development

    Spine Business Development Sales Performance  A-Spine (stock ticker 6758) (新台幣佰萬元) (NT$ millions) Establish June 2001 127 Products spinal implants and instruments 108 100 101 Capital NT$ 135 million 96 81 2020 Sales 81 NT$ 263 million (Q1~Q3) 2020 P/L NT$ 22 million (Q1~Q3) EPS NT$ 1.63 Total asset

  16. Slide 16: USTARII Oncology /Joint Reconstruction System

    USTARII Oncology /Joint Reconstruction System Hub-design structure, obtaining US patent (US10064732B). Launched in USA, the first market where USTARII is available. Leading the industry in product design.

  17. Slide 17: Conformity Stem

    Conformity Stem • Co-developed with orthopedic surgeons from prominent American hospital(HSS). • Varied component and size selections(total 57 pieces), accommodating multiple needs for surgery operations. 17

  18. Slide 18: Locking Cage

    Locking Cage • Unique proprietary “Locking nut” design – Co-developed with the teaching hospital in Taiwan – Patented design facilitates secure acetabular fixation, improving stability and bone healing – 10 cumulative clinical cases have been conducted with good results • Modular system – Diverse se

  19. Slide 19: U2 Knee All-in-One Block (AiO)

    U2 Knee All-in-One Block (AiO)  Facilitating surgeons with easier and more accurate femur sizing and bone resection level measurements  Bronze winner at the 21st Annual Medical Design Excellence Awards Patent No. US9974547 19

  20. Slide 20: Think Surgical Navigation System

    Think Surgical Navigation System  Obtained FDA clearance to use the U2TM Knee System with the TSolution One Total Knee Application in August 2020  40+ clinical cases have been conducted in USA 20

  21. Slide 21: Business Updates

    Business Updates  Continually implementing the rules on prudential operations under the concern of COVID-19.  The launch of new products will mainly drive the company’s sales growth.

  22. Slide 22: Thank you for listening

    Thank you for listening Each Step WeiCare

United Orthopedic — 2020 Investor Conference on 6ix